IL162448A0 - Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor - Google Patents

Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor

Info

Publication number
IL162448A0
IL162448A0 IL16244802A IL16244802A IL162448A0 IL 162448 A0 IL162448 A0 IL 162448A0 IL 16244802 A IL16244802 A IL 16244802A IL 16244802 A IL16244802 A IL 16244802A IL 162448 A0 IL162448 A0 IL 162448A0
Authority
IL
Israel
Prior art keywords
csf
biologically active
stimulating factor
colony stimulating
granulocyte colony
Prior art date
Application number
IL16244802A
Other languages
English (en)
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of IL162448A0 publication Critical patent/IL162448A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL16244802A 2001-12-19 2002-12-05 Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor IL162448A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100322A SI21102A (sl) 2001-12-19 2001-12-19 Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
PCT/EP2002/013810 WO2003051922A1 (en) 2001-12-19 2002-12-05 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
IL162448A0 true IL162448A0 (en) 2005-11-20

Family

ID=20433022

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16244802A IL162448A0 (en) 2001-12-19 2002-12-05 Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor
IL162448A IL162448A (en) 2001-12-19 2004-06-10 Process for the purification and isolation of biologically active granulocyte colony stimulating factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162448A IL162448A (en) 2001-12-19 2004-06-10 Process for the purification and isolation of biologically active granulocyte colony stimulating factor

Country Status (22)

Country Link
US (1) US20050159589A1 (pl)
EP (2) EP1458757B1 (pl)
JP (1) JP4454311B2 (pl)
KR (1) KR20040071212A (pl)
CN (1) CN1606568A (pl)
AT (1) ATE423136T1 (pl)
AU (1) AU2002366275B2 (pl)
BR (1) BR0215191A (pl)
CA (1) CA2469984C (pl)
DE (1) DE60231243D1 (pl)
HK (1) HK1064681A1 (pl)
HR (1) HRP20040572A2 (pl)
HU (1) HUP0402547A3 (pl)
IL (2) IL162448A0 (pl)
MX (1) MXPA04006076A (pl)
NO (1) NO20042967L (pl)
NZ (1) NZ533305A (pl)
PL (1) PL207775B1 (pl)
RU (1) RU2358980C2 (pl)
SI (2) SI21102A (pl)
WO (1) WO2003051922A1 (pl)
ZA (1) ZA200404291B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
ATE322506T1 (de) * 2004-01-19 2006-04-15 Ares Trading Sa Verfahren zur reinigung von in bakterien exprimierten proteinen
EP1803464A4 (en) * 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
WO2006086822A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US20080171857A1 (en) * 2005-03-17 2008-07-17 Uma Devi Komath Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
EP1878739A1 (en) * 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
PT2197919E (pt) 2007-08-27 2014-07-17 Ratiopharm Gmbh Formulação líquida de conjugado de g-csf
JP2009073819A (ja) * 2007-08-29 2009-04-09 Fujifilm Corp 生理活性物質の精製方法
US20120093765A1 (en) * 2009-06-16 2012-04-19 Lupin Limited Process for purification of recombinant human granulocyte colony stimulating factor
MX2011013417A (es) 2009-06-25 2012-03-29 Amgen Inc Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero.
ES2670827T3 (es) * 2010-03-30 2018-06-01 Octapharma Ag Proceso para la purificación del factor estimulador de colonias de granulocitos, G-CSF
SG193545A1 (en) 2011-03-29 2013-11-29 Glaxosmithkline Llc Buffer system for protein purification
CN103215340A (zh) * 2012-01-19 2013-07-24 江苏粒福特生物科技有限公司 一种新颖的粒细胞制备及其抗癌活性检测方法
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
WO1986004605A1 (en) 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5055555A (en) 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5932102A (en) 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes

Also Published As

Publication number Publication date
HRP20040572A2 (en) 2005-06-30
HUP0402547A3 (en) 2010-01-28
JP4454311B2 (ja) 2010-04-21
RU2004121982A (ru) 2005-04-20
KR20040071212A (ko) 2004-08-11
DE60231243D1 (de) 2009-04-02
ATE423136T1 (de) 2009-03-15
WO2003051922A1 (en) 2003-06-26
AU2002366275B2 (en) 2009-04-02
AU2002366275A1 (en) 2003-06-30
US20050159589A1 (en) 2005-07-21
MXPA04006076A (es) 2005-02-24
NO20042967L (no) 2004-09-07
CA2469984A1 (en) 2003-06-26
EP1458757B1 (en) 2009-02-18
SI21102A (sl) 2003-06-30
HUP0402547A2 (hu) 2005-03-29
PL369669A1 (pl) 2005-05-02
CN1606568A (zh) 2005-04-13
PL207775B1 (pl) 2011-01-31
SI1458757T1 (sl) 2009-10-31
EP2053061A1 (en) 2009-04-29
HK1064681A1 (en) 2005-02-04
RU2358980C2 (ru) 2009-06-20
NZ533305A (en) 2005-11-25
EP1458757A1 (en) 2004-09-22
IL162448A (en) 2010-12-30
CA2469984C (en) 2014-05-20
BR0215191A (pt) 2004-11-16
ZA200404291B (en) 2005-08-05
JP2005525304A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
IL162448A0 (en) Process for the purification and/orisolation of biologically active granulocyte colony stimulating factor
ATE226960T1 (de) Verfahren zur herstellung von cardiodilatin- fragmenten, hochgereinigte cardiodilatin- fragmente und zwischenprodukte zu deren herstellung
PL1753778T3 (pl) Sposób oczyszczania erytropoetyny
EP1273592B1 (en) Process for the purification of interferon proteins through cationic exchange chromatography
SI1492878T1 (sl) Postopek za pripravo Ĺľelenega profila gliko-izoform eritropoietina
DE60014047D1 (de) Verfahren zur reinigung von milchsäure auf industrieller basis
BRPI0410685B8 (pt) processos de purificação do 1,3-propanodiol e composição
US9272261B2 (en) Organic-inorganic hybrid chiral sorbent and process for the preparation thereof
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
DK1268399T3 (da) Fremgangsmåde til separering af en basisk aminosyre fra fermenteringsvæske
WO2004060296A3 (en) Sorbent and method for the separation of plasmid dna
EP0895985A3 (en) Method for producing bis(3-amino-4-hydroxyphenyl) compounds
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
CA2210990A1 (en) New combined process for the purification of vancomycin hydrochloride
Ogura et al. An efficient 1, 3-asymmetric induction accompanied with epimerization at the 2-position. Stereoselective reduction of α-substituted β-keto sulfoxides under basic conditions
AU2003302418A1 (en) Method and apparatus for concentration and purification of nucleic acid
DE69001309D1 (de) Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist.
EP1661906A4 (en) METHOD FOR PRODUCING A SOLUTION COMPRISING A COMPOSITION OF BIOLOGICAL COMPONENTS
Kishikawa et al. Enantioseparation of N-(1-arylethyl) amides and α-[N-(3, 5-dinitrobenzoyl)] amino esters by column chromatography. Chiral recognition using a hydrogen bond acceptor centered in a pseudo-C2 symmetric environment. 2
PT1315757E (pt) Processo para a purificação de proteínas epi-hne
Pliura et al. Displacement chromatography process
KR930013133A (ko) 5'-이노신산 함유액의 정제 방법 (i)
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
GEP19980966B (en) Method for Production of Tin (II) Hydroarsenate